Should we be performing sentinel lymph node biopsies for HR+ patients ≥70 years of age?

I do not think that the monarchE data for adjuvant abemaciclib warrants changing our standard practice around omission of SLNB for patients >/= 70 yo with low-risk HR+/HER2- tumors that are clinically node-negative, because adjuvant abemaciclib is largely only appropriate for higher risk tumors and ...

This question brings up another important issue in clinical practice regarding the Commission on Cancer (CoC) Survey Standards requirements.

When a surgeon elects to follow Choosing Wisely recommendations in women >70 years, hormone (+) and a clinically negative axilla, those cases are coded by tumo...